Education
About Us
Working with TipRanks
Follow Us
Harvard Bioscience (HBIO)
:HBIO
HBIO Stock Chart & Stats
$0.40
-$0.02(-0.93%)
At close: 4:00 PM EST
$0.40
-$0.02(-0.93%)
Day’s Range― - ―
52-Week Range$0.28 - $2.61
Previous CloseN/A
Volume27.75K
Average Volume (3M)11.90M
Market Cap
$26.22M
Enterprise ValueN/A
Total Cash (Recent Filing)$6.82M
Total Debt (Recent Filing)$7.33M
Price to Earnings (P/E)―
Beta2.06
Next Earnings
Mar 05, 2026EPS Estimate
0.04Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.00
Shares Outstanding44,531,197
10 Day Avg. Volume34,527,635
30 Day Avg. Volume11,904,357
Financial Highlights & Ratios
PEG Ratio-0.03
Price to Book (P/B)1.45
Price to Sales (P/S)0.98
P/FCF Ratio-76.30
Enterprise Value/Market Cap0.00
Enterprise Value/Revenue0.00
Enterprise Value/Gross Profit0.00
Enterprise Value/Ebitda0.00
Forecast
1Y Price Target
$2.00Price Target Upside400.00% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
European Sales PerformanceIn Europe (EMEA), sales increased sequentially and year-over-year, driven by higher pharma sales.
Product DemandAn expanding backlog and demand for new products prompted a 4Q guide ahead of consensus.
Revenue GrowthHarvard Bioscience 3Q revenue beat consensus and gross margins improved year-over-year, boosted by across-the-board sales execution and financial discipline.
Bears Say
Asian Market DeclineIn China and Asia Pacific (APAC), products declined both sequentially and year-over-year due to tariff concerns.
Government Funding And ShutdownA continuation of the government shutdown and a delay in the release of NIH funding would imply revenue at the lower end of the guidance range.
Market EnvironmentConcerns about basic research funding, drug pricing, and tariffs create an uncertain environment for the sector that seems likely to persist for the near future.
Harvard Bioscience News
HBIO FAQ
What was Harvard Bioscience’s price range in the past 12 months?
Harvard Bioscience lowest stock price was $0.28 and its highest was $2.61 in the past 12 months.
What is Harvard Bioscience’s market cap?
Harvard Bioscience’s market cap is $26.22M.
When is Harvard Bioscience’s upcoming earnings report date?
Harvard Bioscience’s upcoming earnings report date is Mar 05, 2026 which is in 116 days.
How were Harvard Bioscience’s earnings last quarter?
Harvard Bioscience released its earnings results on Nov 06, 2025. The company reported $0 earnings per share for the quarter, missing the consensus estimate of $0.005 by -$0.005.
Is Harvard Bioscience overvalued?
According to Wall Street analysts Harvard Bioscience’s price is currently Undervalued.
Does Harvard Bioscience pay dividends?
Harvard Bioscience does not currently pay dividends.
What is Harvard Bioscience’s EPS estimate?
Harvard Bioscience’s EPS estimate is 0.04.
How many shares outstanding does Harvard Bioscience have?
Harvard Bioscience has 44,531,197 shares outstanding.
What happened to Harvard Bioscience’s price movement after its last earnings report?
Harvard Bioscience reported an EPS of $0 in its last earnings report, missing expectations of $0.005. Following the earnings report the stock price went down -8.475%.
Which hedge fund is a major shareholder of Harvard Bioscience?
Currently, no hedge funds are holding shares in HBIO
Company Description
Harvard Bioscience
Harvard Bioscience (HBIO) is a global provider of innovative tools, instruments, and consumables for life science research. The company operates primarily in the biotechnology and pharmaceutical sectors, offering a wide range of products that facilitate research in areas such as drug discovery, neuroscience, and regenerative medicine. Core products include laboratory instruments, precision measurement devices, and advanced technologies for cellular and molecular biology applications.
HBIO Company Deck
HBIO Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted strong operational improvements, a significant increase in backlog and order growth, successful product launches, and positive cash flow management. However, these positives were somewhat offset by year-over-year revenue decline, challenges in the China market, and uncertainty due to the U.S. government shutdown affecting NIH funding. Overall, the company's efforts to enhance operational efficiency and increase product demand reflect a positive outlook despite some ongoing challenges.View all HBIO earnings summariesHBIO Stock 12 Month Forecast
Average Price Target
$2.00
▲(400.00% Upside)
Technical Analysis
Retractable Technologies
―
EKSO BIONICS
―
Milestone Scientific
―
NexGel Inc
―
Meihua International Medical Technologies Co., Ltd.
―
Ownership Overview
10.08% Insiders
9.35% Mutual Funds
0.46% Other Institutional Investors
76.27% Public Companies and
Individual Investors